Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Trandolapril and verapamil hydrochloride

Drug class: Angiotensin Converting Enzyme Inhibitor

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Trandolapril and verapamil hydrochloride key facts

Drug class
Angiotensin Converting Enzyme Inhibitor
Used for
Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Latest FDA recall
August 14, 2023 (Class III)

Sources: FDA label (January 29, 2026); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Trandolapril and verapamil hydrochloride used for?
The FDA-approved label (Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, January 29, 2026) says: “Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Trandolapril and verapamil hydrochloride?
The “Adverse Reactions” section of the FDA label (Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, January 29, 2026) begins: “Trandolapril and verapamil hydrochloride extended-release tablets have been evaluated in over 1,957 subjects and patients. Of these, 541 patients, including 23% elderly patients, participated in U.S. controlled clinical trials, and 251 were studied in foreign controlled clinical trials. In clinical trials with trandolapril and verapamil hydrochloride extended-release tablets, no adverse experiences peculiar to this combination drug have been observed.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Trandolapril and verapamil hydrochloride?
The “Drug Interactions” section of the FDA label (Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, January 29, 2026) begins: “In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 including CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18. Verapamil has been shown to be an inhibitor of CYP3A4 enzymes and P-glycoprotein (P-gp).” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Trandolapril and verapamil hydrochloride have a boxed warning?
Yes. The FDA label for Trandolapril and Verapamil Hydrochloride has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Trandolapril and verapamil hydrochloride?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Trandolapril and verapamil hydrochloride been recalled?
FDA enforcement reports list 1 recall of products of this medicine; the newest started August 14, 2023 (Class III). A recall usually concerns specific lots, not every product.
Who makes Trandolapril and verapamil hydrochloride?
1 company lists prescription products of Trandolapril and verapamil hydrochloride in the FDA NDC Directory, including Glenmark Pharmaceuticals Inc., USA.

What Trandolapril and verapamil hydrochloride is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). …

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (tablet, film coated, extended release, oral), Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA; it covers 4 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Read it on the full label →

Trandolapril and verapamil hydrochloride boxed warning: what the label says

Quoted from the boxed warning of the FDA-approved label.

WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue trandolapril and verapamil hydrochloride extended-release tablets as soon as possible.
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity).

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. Read the full label on DailyMed →

Trandolapril and verapamil hydrochloride side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

Trandolapril and verapamil hydrochloride extended-release tablets have been evaluated in over 1,957 subjects and patients. Of these, 541 patients, including 23% elderly patients, participated in U.S. controlled clinical trials, and 251 were studied in foreign controlled clinical trials. In clinical trials with trandolapril and verapamil hydrochloride extended-release tablets, no adverse experiences peculiar to this combination drug have been observed.

Read more of this section

Adverse experiences that have occurred have been limited to those that have been previously reported with verapamil or trandolapril. Trandolapril and verapamil hydrochloride extended-release tablets have been evaluated for long-term safety in 272 patients treated for 1 year or more. Adverse experiences were usually mild and transient. Discontinuation of therapy because of adverse events in U.S. placebo-controlled hypertension studies was required in 2.6% and 1.9% of patients treated with trandolapril and verapamil hydrochloride extended-release tablets and placebo, respectively. Adverse experiences occurring in 1% or more of the 541 patients in placebo-controlled hypertension trials who were treated with a range of trandolapril (0.5 to 8 mg) and verapamil (120 to 240 mg) combinations are shown below. ADVERSE EVENTS OCCURRING IN ≥ 1% OF TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE EXTENDED-RELEASE TABLETS PATIENTS IN U.S. PLACEBO-CONTROLLED TRIALS Trandolapril and Verapamil Hydrochloride Extended-Release Tablets (N = 541) % Incidence (% Discontinuance) PLACEBO (N = 206) % Incidence (% Discontinuance) AV Block First Degree 3.9 (0.2) 0.5 (0) Bradycardia 1.8 (0) 0 (0) Bronchitis 1.5 (0) 0.5 (0) Chest Pain 2.2 (0) 1 (0) Constipation 3.3 (0) 1 (0) Cough 4.6 (0) 2.4 (0) Diarrhea 1.5 (0.2) 1 (0) Dizziness 3.1 (0) 1.9 (0.5) Dyspnea 1.3 (0.4) 0 (0) Edema 1.3 (0) 2.4 (0) Fatigue 2.8 (0.4) 2.4 (0) Headache(s) + 8.9 (0) 9.7 (0.5) Increased Liver Enzymes* 2.8 (0.2) 1 (0) Nausea 1.5 (0.2) 0.5 (0) Pain Extremity(ies) 1.1 (0.2) 0.5 (0) Pain Back + 2.2 (0) 2.4 (0) Pain Joint(s) 1.7 (0) 1 (0) Upper Respiratory Tract Infection(s) + 5.4 (0) 7.8 (0) Upper Respiratory Tract Congestion + 2.4 (0) 3.4 (0) * Also includes increase in SGPT, SGOT, Alkaline Phosphatase + Incidence of adverse events is higher in Placebo group than trandolapril and verapamil hydrochloride extended-release tablets patients Other clinical adverse experiences possibly, probably, or definitely related to drug treatment occurring in 0.3% or more of patients treated with trandolapril/verapamil combinations with or without concomitant diuretic in controlled or uncontrolled trials (N = 990) and less frequent, clinically significant events (in italics) include the following: Cardiovascular Angina, AV block second degree, bundle branch block, edema, flushing, hypotension, myocardial infarction, palpitations, premature ventricular contractions, nonspecific ST-T changes, near syncope, tachycardia. Central Nervous System Drowsiness, hypesthesia, insomnia, loss of balance, paresthesia, vertigo. Dermatologic Pruritus, rash. Emotional, Mental, Sexual States Anxiety, impotence, abnormal mentation. Eye, Ear, Nose, Throat Epistaxis, tinnitus, upper respiratory tract infection, blurred vision.

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. This is part of the section. Read the full label on DailyMed →

Trandolapril and verapamil hydrochloride drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

In vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 including CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18. Verapamil has been shown to be an inhibitor of CYP3A4 enzymes and P-glycoprotein (P-gp).

Read more of this section

Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g. erythromycin, ritonavir) causing elevation of plasma levels of verapamil while inducers of CYP3A4 (e.g. rifampin) have caused a lowering of plasma levels of verapamil. Therefore, patients receiving inhibitors or inducers of the cytochrome P450 system should be monitored for drug interactions. Ivabradine Concurrent use of verapamil increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Avoid co-administration of verapamil and ivabradine. Digitalis Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. Chronic verapamil treatment can increase serum digoxin levels by 50 to 75% during the first week of therapy, and this can result in digoxin toxicity. In patients with hepatic cirrhosis, the influence of verapamil on digoxin kinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. Maintenance digoxin doses should be reduced when verapamil is administered, and the patient should be carefully monitored to avoid over- or under-digitalization. Whenever overdigitalization is suspected, the daily dose of digoxin should be reduced or temporarily discontinued. Upon discontinuation of any verapamil-containing regime including trandolapril and verapamil hydrochloride extended-release tablets, the patient should be reassessed to avoid underdigitalization. No clinically significant pharmacokinetic interaction has been found between trandolapril (or its metabolites) and digoxin. Lithium Verapamil Component Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. Trandolapril and verapamil hydrochloride extended-release tablets and lithium should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased. Clarithromycin Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent clarithromycin. Erythromycin Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent erythromycin ethylsuccinate. Cimetidine The interaction between cimetidine and chronically administered verapamil has not been studied.

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. This is part of the section. Read the full label on DailyMed →

Trandolapril and verapamil hydrochloride dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

The recommended usual dosage range of trandolapril for hypertension is 1 to 4 mg per day administered in a single dose or two divided doses. The recommended usual dosage range of verapamil hydrochloride sustained-release tablets for hypertension is 120 to 480 mg per day administered in a single dose or two divided doses.

Read more of this section

The hazards (see WARNINGS) of trandolapril are generally independent of dose; those of verapamil are a mixture of dose-dependent phenomena (primarily dizziness, AV block, constipation) and dose-independent phenomena, the former much more common than the latter. Therapy with any combination of trandolapril and verapamil will thus be associated with both sets of dose-independent hazards. The dose-dependent side effects of verapamil have not been shown to be decreased by the addition of trandolapril nor vice versa. Rarely, the dose-independent hazards of trandolapril are serious. To minimize dose-independent hazards, it is usually appropriate to begin therapy with trandolapril and verapamil hydrochloride extended-release tablets only after a patient has either (a) failed to achieve the desired antihypertensive effect with one or the other monotherapy at its respective maximally recommended dose and shortest dosing interval, or (b) the dose of one or the other monotherapy cannot be increased further because of dose-limiting side effects. Clinical trials with trandolapril and verapamil hydrochloride extended-release tablets have explored only once-a-day doses. The antihypertensive effect and or adverse effects of adding 4 mg of trandolapril once-a-day to a dose of 240 mg verapamil hydrochloride sustained-release tablets administered twice-a-day has not been studied, nor have the effects of adding as little of 180 mg verapamil hydrochloride sustained-release tablets to 2 mg trandolapril administered twice-a-day been evaluated. Over the dose range of verapamil hydrochloride sustained-release tablets 120 to 240 mg once-a-day and trandolapril 0.5 to 8 mg once-a-day, the effects of the combination increase with increasing doses of either component. Replacement Therapy For convenience, patients receiving trandolapril (up to 8 mg) and verapamil (up to 240 mg) in separate tablets, administered once-a-day, may instead wish to receive trandolapril and verapamil hydrochloride extended-release tablets containing the same component doses. Trandolapril and verapamil hydrochloride extended-release tablets should be administered with food.

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. Read the full label on DailyMed →

Trandolapril and verapamil hydrochloride in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Female patients of childbearing age should be told about the consequences of exposure to trandolapril and verapamil hydrochloride extended-release tablets during pregnancy (see WARNINGS). Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. Read the full label on DailyMed →

Trandolapril and verapamil hydrochloride and breastfeeding

Quoted from the nursing mothers / lactation part of the FDA-approved label.

Verapamil is excreted in human milk. Radiolabeled trandolapril or its metabolites are secreted in rat milk. Trandolapril and verapamil hydrochloride extended-release tablets should not be administered to nursing mothers.

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. Read the full label on DailyMed →

When Trandolapril and verapamil hydrochloride should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients who are hypersensitive to any ACE inhibitor or verapamil. Because of the verapamil component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in: 1. Severe left ventricular dysfunction (see WARNINGS). 2. Hypotension (systolic pressure less than 90 mmHg) or cardiogenic shock. 3.

Read more of this section

Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). 5. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g. Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) (see WARNINGS). 6. Patients taking flibanserin (see PRECAUTIONS - Drug Interactions). Because of the trandolapril component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme (ACE) inhibitor. Do not co-administer aliskiren with trandolapril and verapamil hydrochloride extended-release tablets in patients with diabetes (see PRECAUTIONS - Drug Interactions). Trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer trandolapril and verapamil hydrochloride extended-release tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS).

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. Read the full label on DailyMed →

Trandolapril and verapamil hydrochloride overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

No specific information is available on the treatment of overdosage with trandolapril and verapamil hydrochloride extended-release tablets. Verapamil Component Overdose with verapamil may lead to pronounced hypotension, bradycardia, and conduction system abnormalities (e.g., junctional rhythm with AV dissociation and high degree AV block, including asystole).

Read more of this section

Other symptoms secondary to hypoperfusion (e.g., metabolic acidosis, hyperglycemia, hyperkalemia, renal dysfunction, and convulsions) may be evident. Treat all verapamil overdoses as serious and maintain observation for at least 48 hours, preferably under continuous hospital care. Delayed pharmacodynamic consequences may occur with the sustained release formulation. Verapamil is known to decrease gastrointestinal transit time. In cases of overdose, verapamil hydrochloride sustained-release tablets have occasionally been reported to form concretions within the stomach or intestines. These concretions have not been visible on plain radiographs of the abdomen, and no medical means of gastrointestinal emptying is of proven efficacy in removing them. Endoscopy might reasonably be considered in cases of overdose when symptoms are unusually prolonged. Verapamil cannot be removed by hemodialysis. Treatment of overdosage should be supportive. Beta adrenergic stimulation or parenteral administration of calcium solutions may increase calcium ion flux across the slow channel, and have been used effectively in treatment of deliberate overdosage with verapamil. The following measures may be considered: Bradycardia and Conduction System Abnormalities Atropine, isoproterenol, and cardiac pacing. Hypotension Intravenous fluids, vasopressors (e.g., dopamine, dobutamine), calcium solutions (e.g., 10% calcium chloride solution). Cardiac Failures Inotropic agents (e.g., isoproterenol, dopamine, dobutamine), diuretics. Asystole should be handled by the usual measures including cardiopulmonary resuscitation. Trandolapril Component The oral LD 50 of trandolapril in mice was 4875 mg/kg in males and 3990 mg/kg in females. In rats, an oral dose of 5000 mg/kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/kg did not cause mortality and abnormal clinical signs were not observed. In humans, the most likely clinical manifestation would be symptoms attributable to severe hypotension. Laboratory determinations of serum levels of trandolapril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of trandolapril overdose. No data are available to suggest that physiological maneuvers (e.g., maneuvers to change pH of the urine) might accelerate elimination of trandolapril and its metabolites. It is not known if trandolapril or trandolaprilat can be usefully removed from the body by hemodialysis. Angiotensin II could presumably serve as a specific antagonist antidote in the setting of trandolapril overdose, but angiotensin II is essentially unavailable outside of scattered research facilities.

— FDA label: Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026. This is part of the section. Read the full label on DailyMed →

Forms and how it is given

Dosage formsTablet, film coated, extended release
RouteOral
Prescription products4 in the FDA NDC Directory

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.

Generic approvals (1)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. August 14, 2023 · Class III · Ongoing · D-1095-2023

    Subpotent: Out of Specification for Assay Test at the 3-month time point.

    Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pha — Glenmark Pharmaceuticals Inc., USA

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

RxCUI (RxNorm)897781, 897783, 897844, 897853
SPL set ID of the quoted label39bad727-af4c-4d20-933b-7f287e88099a
FDA labels (SPL)1
FDA applications1 ANDA
Active ingredients (FDA)TRANDOLAPRIL / VERAPAMIL

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Trandolapril and Verapamil Hydrochloride, Glenmark Pharmaceuticals Inc., USA, effective January 29, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers